摘要
Objective: To study the effects of parecoxib + dexmedetomidine on systemic inflammation and oxidative stress during anesthesia recovery period of thoracoscopic surgery. Methods:The lung cancer patients undergoing thoracoscopic surgery in Kailuan General Hospital between March 2015 and February 2018 were selected as the research subjects and randomly divided into the experimental group who received parecoxib + dexmedetomidine preemptive analgesia combined with conventional anesthesia and the control group who received conventional anesthesia. 3 and 5 d after surgery, serum was collected to measure the contents of inflammatory cytokines interferon-γ (IFN-γ), interleukin-1β (IL-1β), interleukin-18 (IL-18), intercellular adhesion molecule-1 (ICAM1) and monocyte chemoattractant protein-1 (MCP1) as well as oxidative stress mediators cortisol (COR), malondialdehyde (MDA), endothelin-1 (ET-1), superoxide dismutase (SOD) and total antioxidant capacity (T-AOC), and peripheral anticoagulant blood was collected to measure the expressions of inflammatory signaling molecules Toll-like receptor 4 (TLR4), NOD-like receptor protein 3 (NLRP3), nuclear factor-κB (NF-κB), apoptosis-associated speck-like protein containing CARD (ASC) and cysteinyl aspartate specific proteinase-1 (caspase-1) as well as oxidative stress molecules nuclear factor E2-related factor 2 (NRF2), antioxidant response element (ARE), NADPH oxidase (NOX) 2 and NOX4. Results: 3 and 5 d after surgery, serum IFN-γ, IL-1β, IL-18, ICAM1, MCP1, COR, MDA and ET-1 contents as well as peripheral blood TLR4, NLRP3, NF-κB, ASC, Caspase-1, NRF2, ARE, NOX2 and NOX4 expression intensity of the experimental group were significantly lower than those of the control group whereas serum SOD and T-AOC contents were higher than those of the control group. Conclusion: Parecoxib+ dexmedetomidine can inhibit the systemic inflammation and oxidative stress during anesthesia recovery period of thoracoscopic surgery.
